Literature DB >> 11292722

Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting.

A Tanghe1, S D'Souza, V Rosseels, O Denis, T H Ottenhoff, W Dalemans, C Wheeler, K Huygen.   

Abstract

C57BL/6 mice were vaccinated with plasmid DNA encoding Ag85 from Mycobacterium tuberculosis, with Ag85 protein in adjuvant, or with a combined DNA prime-protein boost regimen. While DNA immunization, as previously described, induced robust Th1-type cytokine responses, protein-in-adjuvant vaccination elicited very poor cytokine responses, which were 10-fold lower than those observed with DNA immunization alone. Injection of Ag85 DNA-primed mice with 30 to 100 microg of purified Ag85 protein in adjuvant increased the interleukin-2 and gamma interferon (IFN-gamma) response in spleen two- to fourfold. Further, intracellular cytokine analysis by flow cytometry also showed an increase in IFN-gamma-producing CD4(+) T cells in DNA-primed-protein-boosted animals, compared to those that received only the DNA vaccination. Moreover, these responses appeared to be better sustained over time. Antibodies were readily produced by all three methods of immunization but were exclusively of the immunoglobulin G1 (IgG1) isotype following protein immunization in adjuvant and preferentially of the IgG2a isotype following DNA and DNA prime-protein boost vaccination. Finally, protein boosting increased the protective efficacy of the DNA vaccine against an intravenous M. tuberculosis H37Rv challenge infection, as measured by CFU or relative light unit counts in lungs 1 and 2 months after infection. The capacity of exogenously given protein to boost the DNA-primed vaccination effect underlines the dominant role of Th1-type CD4(+) helper T cells in mediating protection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11292722      PMCID: PMC98258          DOI: 10.1128/IAI.69.5.3041-3047.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  37 in total

1.  Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination.

Authors:  N L Letvin; D C Montefiori; Y Yasutomi; H C Perry; M E Davies; C Lekutis; M Alroy; D C Freed; C I Lord; L K Handt; M A Liu; J W Shiver
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

2.  Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis.

Authors:  J T Belisle; V D Vissa; T Sievert; K Takayama; P J Brennan; G S Besra
Journal:  Science       Date:  1997-05-30       Impact factor: 47.728

3.  Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit.

Authors:  S W Barnett; S Rajasekar; H Legg; B Doe; D H Fuller; J R Haynes; C M Walker; K S Steimer
Journal:  Vaccine       Date:  1997-06       Impact factor: 3.641

4.  Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara.

Authors:  J Schneider; S C Gilbert; T J Blanchard; T Hanke; K J Robson; C M Hannan; M Becker; R Sinden; G L Smith; A V Hill
Journal:  Nat Med       Date:  1998-04       Impact factor: 53.440

5.  Immunogenicity and protective efficacy of a tuberculosis DNA vaccine.

Authors:  K Huygen; J Content; O Denis; D L Montgomery; A M Yawman; R R Deck; C M DeWitt; I M Orme; S Baldwin; C D'Souza; A Drowart; E Lozes; P Vandenbussche; J P Van Vooren; M A Liu; J B Ulmer
Journal:  Nat Med       Date:  1996-08       Impact factor: 53.440

6.  Vaccination with plasmid DNA encoding mycobacterial antigen 85A stimulates a CD4+ and CD8+ T-cell epitopic repertoire broader than that stimulated by Mycobacterium tuberculosis H37Rv infection.

Authors:  O Denis; A Tanghe; K Palfliet; F Jurion; T P van den Berg; A Vanonckelen; J Ooms; E Saman; J B Ulmer; J Content; K Huygen
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

7.  Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis.

Authors:  M A Horwitz; B W Lee; B J Dillon; G Harth
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

8.  Mapping of TH1 helper T-cell epitopes on major secreted mycobacterial antigen 85A in mice infected with live Mycobacterium bovis BCG.

Authors:  K Huygen; E Lozes; B Gilles; A Drowart; K Palfliet; F Jurion; I Roland; M Art; M Dufaux; J Nyabenda
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

9.  Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins.

Authors:  P Andersen
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

10.  Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting.

Authors:  J F Richmond; S Lu; J C Santoro; J Weng; S L Hu; D C Montefiori; H L Robinson
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

View more
  46 in total

1.  Partial reconstitution of the CD4+-T-cell compartment in CD4 gene knockout mice restores responses to tuberculosis DNA vaccines.

Authors:  Sushila D'Souza; Marta Romano; Johanna Korf; Xiao-Ming Wang; Pierre-Yves Adnet; Kris Huygen
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

Review 2.  On the use of DNA vaccines for the prophylaxis of mycobacterial diseases.

Authors:  Kris Huygen
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

3.  CD8+-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2.

Authors:  Adriano F S Araújo; Bruna C G de Alencar; José Ronnie C Vasconcelos; Meire I Hiyane; Cláudio R F Marinho; Marcus L O Penido; Silvia B Boscardin; Daniel F Hoft; Ricardo T Gazzinelli; Mauricio M Rodrigues
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

4.  Optimization of codon usage enhances the immunogenicity of a DNA vaccine encoding mycobacterial antigen Ag85B.

Authors:  Hyun-Jeong Ko; Sung-Youl Ko; Yeon-Jeong Kim; Eun-Gae Lee; Sang-Nae Cho; Chang-Yuil Kang
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

5.  Enhanced immunogenicity and protective efficacy with the use of interleukin-12-encapsulated microspheres plus AS01B in tuberculosis subunit vaccination.

Authors:  Sang-Jun Ha; Su-Hyung Park; Hye-Ju Kim; Seung-Chul Kim; Hyang-Ju Kang; Eun-Gae Lee; Soon-Geon Kwon; Byong-Moon Kim; Sung-Hee Lee; Won-Bae Kim; Young-Chul Sung; Sang-Nae Cho
Journal:  Infect Immun       Date:  2006-08       Impact factor: 3.441

6.  Gamma interferon and monophosphoryl lipid A-trehalose dicorynomycolate are efficient adjuvants for Mycobacterium tuberculosis multivalent acellular vaccine.

Authors:  Avi-Hai Hovav; Yolanta Fishman; Herve Bercovier
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

7.  Enhanced in vivo gene expression mediated by listeriolysin O incorporated anionic LPDII: Its utility in cytotoxic T lymphocyte-inducing DNA vaccine.

Authors:  Xun Sun; Chester Provoda; Kyung-Dall Lee
Journal:  J Control Release       Date:  2010-07-07       Impact factor: 9.776

8.  Genetic resistance of mice to Mycobacterium paratuberculosis is influenced by Slc11a1 at the early but not at the late stage of infection.

Authors:  Virginie Roupie; Valérie Rosseels; Virginie Piersoel; Denise K Zinniel; Raúl G Barletta; Kris Huygen
Journal:  Infect Immun       Date:  2008-02-19       Impact factor: 3.441

9.  Induction of Specific CD8 T Cells against Intracellular Bacteria by CD8 T-Cell-Oriented Immunization Approaches.

Authors:  Toshi Nagata; Yukio Koide
Journal:  J Biomed Biotechnol       Date:  2010-05-24

10.  Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guérin.

Authors:  H Martin Vordermeier; Shelley G Rhodes; Gillian Dean; Nilu Goonetilleke; Kris Huygen; Adrian V S Hill; R Glyn Hewinson; Sarah C Gilbert
Journal:  Immunology       Date:  2004-07       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.